Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study
Authors:
- Fabrice GiraudetFGFabrice Giraudet
- Marie SelvyMSMarie Selvy
- Nicolas KerckhoveNKNicolas Kerckhove
- Bruno PereiraBruno Pereira
- Daniel NguyenDNDaniel Nguyen
- Jérôme BusserollesJBJérôme Busserolles
- Aurélie CabrespineACAurélie Cabrespine
- Martin SoubrierMSMartin Soubrier
- Jacques-Olivier BayJBJacques-Olivier Bay
- Richard LemalRLRichard Lemal
- 31 January 2022
- journal article
- research article
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 279 (4) , 2197-2201
Abstract
Purpose Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties. Methods Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients’ characteristics and anticancer treatments. Results The prevalence of auditory difficulties was about 42.4% (95% CI [30.6–55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman’s coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0–117.1], p = 0.002). Conclusion This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib. Trial registration number: NCT03344328.Keywords
This publication has 18 references indexed in Scilit:
- Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature ReviewFrontiers in Pharmacology, 2017
- Multiple myeloma epidemiology and survival: A unique malignancySeminars in Oncology, 2016
- Hypervulnerability to Sound Exposure through Impaired Adaptive Proliferation of PeroxisomesCell, 2015
- Peroxisomes Get Loud: A Redox Antidote to Hearing LossCell, 2015
- Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunctionBiochemical and Biophysical Research Communications, 2015
- Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coinAnnals of Oncology, 2013
- Deafness associated with the use of Bortezomib in multiple myelomaActa Oncologica, 2008
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- Severe irreversible bilateral hearing loss after bortezomib (VELCADE®) therapy in a multiple myeloma (MM) patientLeukemia, 2005
- The Speech, Spatial and Qualities of Hearing Scale (SSQ)International Journal of Audiology, 2004